The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension

Comparison of Ocular Hypotensive Effect and Safety of Brinzolamide and Timolol Added to Latanoprost

“…For systemic adverse reactions associated with brinzolamide monotherapy, the incidence of dysgeusia was reported to be 3.0% to 3.3%. 14,15 To the best of our knowledge, facial hot flushes have not been reported. The present study demonstrated that brinzolamide and timolol, when added to latanoprost monotherapy, produced similar reductions in IOP.…”

“…14 When the ocular hypotensive effect of brinzolamide alone was compared with that of timolol alone, brinzolamide was slightly inferior. 15,16 In addition, ophthalmic prostaglandins were reported to have an effect on carbonic anhydrase activity. 17 This suggests an interaction between ophthalmic prostaglandins and carbonic anhydrase inhibitors with respect to the ocular hypotensive effect.…”

Intraocular Pressure-lowering Efficacy of Brinzolamide When Added to Travoprost/Timolol Fixed Combination as Adjunctive Therapy

“…[4][5][6] Brinzolamide, however, has demonstrated less stinging than dorzolamide in several clinical trials. 4,[7][8][9] Unfortunately, little information exists on the use of a CAI as third-line therapy, when added to a prostaglandin and b-blocker.…”

Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy

“…It is effective in the short-and long-term treatment of patients with glaucoma or ocular hypertension and in reducing IOP after phacoemulsification cataract surgery. [10][11][12][13] Apraclonidine reduces IOP by reducing aqueous production and increasing uveoscleral outflow. 19 However, the uveoscleral outflow effect occurs only with prolonged treatment.…”

“…8,9 It is effective in the short-and long-term treatment of patients with glaucoma or ocular hypertension and in reducing IOP after phacoemulsification cataract surgery. [10][11][12][13] To our knowledge, there are no published reports of the effectiveness of brinzolamide in preventing IOP elevation after laser treatment. This study examined the IOPlowering effects of brinzolamide 1% and apraclonidine 0.5% for prophylaxis of IOP elevation after Nd:YAG laser posterior capsulotomy.…”